Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML.
Todd M. Cooper(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Jacob Appelbaum(National Cancer Institute), Jordan Jarjour(Biogen (United States)), Joshua D. Gustafson, Stephanie Mgebroff(Bloodworks Northwest), Christopher A. Brown, Catherine Lindgren(Unknown), Vicky Wu(Fred Hutch Cancer Center), Michael C. Jensen(Seattle Children's Hospital)
Cited by 8
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754